Rheumatoid arthritis (hereinafter referred to as classes wind) belong to the autoimmune disease, is a common cause of chronic systemic connective tissue diseases can cause serious malformations. Current cause is not well understood, but it's very difficult to treat. In drug treatment, class RA treatments, including traditional medicines and Biologics. Traditional medicines include non-steroidal anti-inflammatory drugs (NSAIDS), corticosteroids, and improve the condition of the traditional anti-rheumatic drugs (DMARDs) and biological agents can quickly take effect, relieve symptoms, improve the patient's quality of life. Since entering the 21st century, it 10-20 years of last century, the emergence of tumor necrosis factor TNF antagonists, greatly improving the kind of treatment the prognosis in patients with RA, became the core of last more than 10 years wind treatment drugs. This is TFN-alpha of inflammatory factors of biological agents. It has a very good effect, but is not effective in all patients. So there are a lot of new biological agent appear.
On February 23, "type of wind-new choice for biological agents" of Chinese and foreign experts on media day, Peking Union Medical College Hospital for rheumatic, Deputy Director of Rheumatology branch of the Chinese Medical Association Chairman, rheumatic general practitioner branch of the Chinese medical doctor Association said Professor Zeng Xiaofeng, President-designate, in 21st century is the era of Biologics. New technologies are emerging, new biological agents are also emerging, for doctors will be new challenges, new knowledge of biological agents. Answer the interview questions BioValley, Professor Zeng Xiaofeng said that there are many types of RA patients because there is no effective treatment and lead to eventual disability, joint deformity, loss of ability to live. Biological agents in the treatment of these patients have the opportunity to avoid these consequences, improve their lives, and can even prolong the patient's life.